ArticleBMC public health2026
Trends in methylphenidate dispensing and regional inequalities among children and adolescents in France around the 2021 prescription reform: a repeated cross-sectional ecological analysis of national data (2014-2024).
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2021, France broadened methylphenidate prescribing conditions by allowing treatment initiation outside hospital-based specialist settings in children and adolescents. This regulatory change occurred during the COVID-19 period and alongside broader changes in attention-deficit/hyperactivity disorder (ADHD) recognition and care organization, making its specific effect difficult to disentangle from concurrent contextual factors. We therefore examined national trends in methylphenidate dispensing and regional inequalities in France over 2014-2024, interpreting the reform and pandemic period as contextual factors rather than isolated causal exposures.
methodsWe conducted a repeated cross-sectional ecological study using annual region-level aggregated data from OPENMEDIC and INSEE for individuals aged 0-19 years in France from 2014 to 2024. OPENMEDIC records dispensed boxes rather than treatment initiations or treated individuals. Pre- and post-periods were defined as 2014-2019 and 2022-2024; 2020-2021 were treated as transition years. The primary outcome was annual methylphenidate dispensations per 1,000 inhabitants. Secondary outcomes included methylphenidate as a proportion of all psychotropic dispensations and regional inequality indices. All analyses were interpreted descriptively.
resultsMethylphenidate dispensations per 1,000 inhabitants aged 0-19 years increased across all 13 French regions in 2022-2024 compared with 2014-2019. Nationally, dispensations rose from 0.058 per 1,000 in 2014 to 0.189 per 1,000 in 2024, corresponding to a 3.3-fold increase. In descriptive national and panel analyses, post-2022 slopes were steeper than pre-period slopes, whereas immediate level-change estimates were imprecise. The national proportion of methylphenidate among all psychotropic dispensations increased from 6.30% in 2014-2019 to 9.09% in 2022-2024. Regional inequality metrics showed no clear convergence.
conclusionsIn this nationwide ecological study based on annually aggregated data, methylphenidate dispensing more than tripled in France between 2014 and 2024, with steeper post-2022 trends, while regional disparities remained observable and showed no clear convergence. Because the 2021 prescription reform coincided with the COVID-19 period and other changes in ADHD care, these findings should be interpreted as descriptive population-level trends rather than evidence of a specific reform effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.